GGrantIndex
← Leaderboards

Geneva Foundation

Tacoma, WA

Compare ↔
$42,677,157
Total funding
19
Grants

Funding over time

peak $6.5M · FY2006–23
$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$42,677,157 · 19

By mechanism

R01$19,305,135 · 5
U01$11,157,610 · 4
N01$9,431,838 · 4
R21$1,668,504 · 5
R33$1,114,070 · 1

Investigators at Geneva Foundation

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

1Elke Bergmannleitner$391,5302 gr

Emerging Leaders

6–10 yrs in

1Kathleen A Cashman$785,0311 gr2Lucille Lange$669,3122 gr

All-Time

Most funded here, all years

1Jay Williams Hooper$7,880,7722 gr2Robert G. Ulrich$4,357,9551 gr3John M Dye$3,551,5221 gr4Connie Schmaljohn$2,729,8551 gr5Sina Bavari$1,453,0692 gr6Kathleen A Cashman$785,0311 gr7Lucille Lange$669,3122 gr8Elke Bergmannleitner$391,5302 gr

Largest grants

Development of Technologies that Accelerate the Immune Response to Vaccines$4,505,171
N01 · FY2018 · AI
Development of Technologies that Accelerate the Immune Response to Vaccines$2,601,888
N01 · FY2012 · AI
Development of Technologies that Accelerate the Immune Response to Vaccines$1,105,831
N01 · FY2015 · AI
Integrated polymer microfluidic device for multiplex diagnosis of viral infection$1,088,801
R01 · FY2011 · AI
Advancing a Candidate Polyclonal Antibody Therapy for Hantavirus Disease$1,079,215
R01 · FY2019 · AI
Advancing a Candidate Polyclonal Antibody Therapy for Hantavirus Disease$1,055,169
R01 · FY2018 · AI
Advancing a Candidate Polyclonal Antibody Therapy for Hantavirus Disease$1,049,794
R01 · FY2020 · AI
Advancing a Candidate Polyclonal Antibody Therapy for Hantavirus Disease$1,037,264
R01 · FY2017 · AI
Assessment of the Immunogenicity and Protective Efficacy of a Multiagent DNA Vacc$1,031,332
U01 · FY2010 · AI
Second Generation Small Molecule Inhibitors of Botulinum Neurotoxins$956,837
U01 · FY2011 · AI
Second Generation Small Molecule Inhibitors of Botulinum Neurotoxins$954,452
U01 · FY2012 · AI
Mammalian and Plant-derived Antibody-based Therapies against Sudan Ebolavirus$917,343
R01 · FY2017 · AI
Second Generation Small Molecule Inhibitors of Botulinum Neurotoxins$896,077
U01 · FY2013 · AI
Second Generation Small Molecule Inhibitors of Botulinum Neurotoxins$866,638
U01 · FY2010 · AI
Integrated polymer microfluidic device for multiplex diagnosis of viral infection$837,646
R01 · FY2015 · AI
Integrated polymer microfluidic device for multiplex diagnosis of viral infection$834,797
R01 · FY2014 · AI
Integrated polymer microfluidic device for multiplex diagnosis of viral infection$823,047
R01 · FY2012 · AI
Development of Technologies that Accelerate the Immune Response to Vaccines$821,269
N01 · FY2016 · AI
Second Generation Small Molecule Inhibitors of Botulinum Neurotoxins$814,793
U01 · FY2009 · AI
Mammalian and Plant-derived Antibody-based Therapies against Sudan Ebolavirus$786,345
R01 · FY2018 · AI